With a phase III candidate that CEO Matthew Pauls said could be positioned as "the first-line, first-choice medicinal therapy for Cushing's syndrome [CS]," Strongbridge Pharma plc kicked off a second late-stage trial to test Recorlev (levoketoconazole), an oral cortisol synthesis inhibitor.